Pmv Pharmaceuticals
Manufacturing · New Jersey, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
1 Research Way, Princeton, New Jersey, 0...Phone Number
(609) 642-6670Website
www.pmvpharma.comRevenue
$9.9 MillionStock Symbol
PMVPIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
1
1
1
About Pmv Pharmaceuticals
PMV Pharmaceuticals, Inc. is a clinical-stage precision oncology company incorporated in 2013 and headquartered in Princeton, New Jersey. The company is focused on the research and development of small molecule therapies that target mutant p53, one of the most commonly altered tumor suppressor genes in human cancer. PMV's approach centers on structurally correcting the precise geometry of mutant p53 proteins to restore their tumor-suppressing function, enabling tumor-agnostic treatment strategies applicable across a broad range of cancer types. The company's research and development efforts are dedicated to selectively targeting p53 mutations in patients whose tumors harbor these gene alterations. PMV went public in September 2020 and trades on the NASDAQ Global Select Market under the ticker symbol PMVP.Explore more
Pmv Pharmaceuticals Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Pmv Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Pmv Pharmaceuticals has new funding data
Earning: See what the market has to say on Pmv Pharmaceuticals recently announced quarterly report
Click to see if Pmv Pharmaceuticals had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Pmv Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Pmv Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Pmv Pharmaceuticals launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Pmv Pharmaceuticals is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Pmv Pharmaceuticals
Recommended Actions
Reach out to Masked Content who joined Pmv Pharmaceuticals as Masked Content
Find 2 more new buyers
Compare Similar Companies to Pmv Pharmaceuticals
Compare insights from companies similar to Pmv Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Pmv Pharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Pmv Pharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Pmv Pharmaceuticals.
Pmv Pharmaceuticals financials insights
Gather financial insights about Pmv Pharmaceuticals, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2014
Series A
$30M
2017
Series B
$74M
2019
Series C
$62M
2020
Series D
$70M
Stock Offering
$212M
Pmv Pharmaceuticals Tech Stack
A closer look at the technologies used by Pmv Pharmaceuticals
Most Recent Scoops
Executive Move
Executive Moves, Board of Directors
Executive Move
Executive Moves, Board of Directors
Open Position
Partnership
Project
Laboratory Operations, Medical Research, Clinical Operations
Partnership
Project
Laboratory Operations, Medical Research, Clinical Operations
Pmv Pharmaceuticals News & Media
PMV Pharmaceuticals Announces Board Chair Transition
Rich Heyman to retire from PMV Pharma Board of Directors; Laurie Stelzer, Director since 2020, appointed as new Chair Rich Heyman to retire from PMV Pharma Board of Directors; Laurie Stelzer, Director since 2020, appointed as new ChairPMV Pharmaceuticals Reports Full Year 2025 Financial Results and Corporate Highlights
PRINCETON, N.J., March 06, 2026 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule therapies targeting p53, today reported financial results for the full year ended December 31, 2025, and provided a corporate update.New England Journal of Medicine Publishes First-in-Human Rezatapopt Data Showing Selective Reactivation of Mutant p53 in Advanced Solid Tumors
PRINCETON, N.J., Feb. 26, 2026 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule therapies targeting p53, today announced that results from the Phase 1, first-in-human portion of the ongoing Phase 1/2 PYNNACLE study evaluating rezatapopt in patients with advanced solid tumors harboring a TP53 Y220C mutation were published in the New England Journal of Medicine (NEJM)PMV Pharmaceuticals Reports Third Quarter 2025 Financial Results and Corporate Highlights
PRINCETON, N.J., Nov. 12, 2025 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule therapies targeting p53, today reported financial results for the third quarter ended September 30, 2025, and provided a corporate update.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Pmv Pharmaceuticals
Sign Up For FreeTo access detailed company insights
PMV Pharmaceuticals, Inc. is a clinical-stage precision oncology company incorporated in 2013 and headquartered in Princeton, New Jersey. The company is focused on the research and development of small molecule therapies that target mutant p53, one of the most commonly altered tumor suppressor genes in human cancer. PMV's approach centers on struct... Read More
